Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Fate Therapeutics, Inc. provides biotechnology services. The Company researches and develops therapies to repair and regenerate body tissues with the help of stem cells. Fate Therapeutics conducts business in the United States.
Website: fatetherapeutics.com



Growth: Good revenue growth rate 50.0%, there is acceleration compared to average historical growth rates 29.9%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1 292.9%. On average the margin is decreasing steadily. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.17 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 10.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 45.1% higher than minimum and 88.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -59.6x by EV / Sales multiple

Key Financials (Download financials)

Ticker: FATE
Share price, USD:  (0.0%)0.9864
year average price 1.1474  


year start price 1.2900 2025-01-13

max close price 1.7100 2025-02-19

min close price 0.6800 2025-04-03

current price 0.9864 2026-01-12
Common stocks: 96 629 106

Dividend Yield:  0.0%
EV / Sales: 11.2x
Margin (EBITDA LTM / Revenue): -1 292.9%
Fundamental value created in LTM:
Market Cap ($m): 95
Net Debt ($m): 61
EV (Enterprise Value): 156
Price to Book: 0.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-11-13zacks.com

Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates

2025-10-28zacks.com

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

2025-08-12zacks.com

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

2025-06-12zacks.com

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?

2025-05-30globenewswire.com

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

2025-04-15zacks.com

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

2025-03-05zacks.com

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

2025-02-17zacks.com

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know

2025-02-14globenewswire.com

Fate Therapeutics to Present at Upcoming Investor Conferences

2025-02-04seekingalpha.com

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-12 2024-11-12 2024-08-13 2024-05-09 2024-02-26 2023-11-08 2023-08-08 2023-05-03 2023-02-28 2022-11-03
acceptedDate 2025-11-13 08:35:02 2025-08-12 16:09:49 2024-11-12 16:03:31 2024-08-13 16:08:07 2024-05-09 16:05:10 2024-02-26 16:10:56 2023-11-08 16:05:27 2023-08-08 16:09:52 2023-05-03 16:10:07 2023-02-28 16:06:30 2022-11-03 16:05:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 2M 2M 3M 7M 2M 2M 2M 933 000 59M 44M 15M
costOfRevenue 0 0 0 35M 5M 5M 5M 0 0 0 0
grossProfit 2M 2M 3M -28M -3M -3M -3M 933 000 59M 44M 15M
grossProfitRatio 1 1 1 -4.11 -1.504 -1.915 -1.438 1 1 1 1
researchAndDevelopmentExpenses 26M 27M 35M 35M 27M 27M 34M 41M 66M 87M 80M
generalAndAdministrativeExpenses 11M 11M 21M 17M 21M 18M 19M 23M 22M 22M 22M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 11M 11M 21M 17M 21M 18M 19M 23M 22M 22M 22M
otherExpenses 0 0 0 0 -1M -3M 1M 5M 6M 5M 0
operatingExpenses 36M 39M 55M 52M 48M 45M 53M 63M 88M 109M 101M
costAndExpenses 36M 39M 55M 52M 53M 50M 53M 63M 88M 109M 101M
interestIncome 3M 3M 4M 5M 4M 4M 5M 4M 4M 3M 2M
interestExpense 0 0 0 0 0 10M 0 0 -10M 3M 2M
depreciationAndAmortization 3M 3M 0 5M 5M 5M 5M 4M 4M 5M 8M
ebitda -29M -31M -52M -40M -46M -43M -51M -58M -24M -64M -79M
ebitdaratio -16.67 -16.147 -17.039 -5.96 -24.024 -25.77 -26.378 -62.271 -0.414 -1.452 -5.246
operatingIncome -35M -37M -52M -45M -51M -48M -51M -63M -29M -64M -86M
operatingIncomeRatio -19.951 -19.385 -17.039 -6.657 -26.529 -28.684 -26.378 -67.058 -0.485 -1.452 -5.767
totalOtherIncomeExpensesNet 2M 3M 5M 7M 3M 4M 6M 5M 10M 8M 3M
incomeBeforeTax -32M -34M -48M -38M -48M -44M -45M -53M -19M -56M -84M
incomeBeforeTaxRatio -18.524 -17.866 -15.51 -5.674 -24.937 -26.326 -23.236 -56.543 -0.32 -1.271 -5.578
incomeTaxExpense 0 0 0 0 5M 19M -5M -4M -10M -8M -3M
netIncome -32M -34M -48M -38M -48M -44M -45M -53M -9M -48M -81M
netIncomeRatio -18.524 -17.866 -15.51 -5.674 -24.937 -26.326 -23.236 -56.543 -0.155 -1.089 -5.389
eps -0.27 -0.29 -0.4 -0.33 -0.47 -0.45 -0.46 -0.54 -0.094 -0.5 -0.83
epsdiluted -0.27 -0.29 -0.4 -0.33 -0.47 -0.45 -0.46 -0.54 -0.094 -0.5 -0.83
weightedAverageShsOut 119M 119M 118M 117M 101M 99M 99M 98M 98M 97M 97M
weightedAverageShsOutDil 119M 119M 118M 117M 101M 99M 99M 98M 98M 97M 97M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-12 2024-11-12 2024-08-13 2024-05-09 2024-02-26 2023-11-08 2023-08-08 2023-05-03 2023-02-28 2022-11-03
acceptedDate 2025-11-13 08:35:02 2025-08-12 16:09:49 2024-11-12 16:03:31 2024-08-13 16:08:07 2024-05-09 16:05:10 2024-02-26 16:10:56 2023-11-08 16:05:27 2023-08-08 16:09:52 2023-05-03 16:10:07 2023-02-28 16:06:30 2022-11-03 16:05:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 41M 41M 38M 37M 121M 42M 33M 47M 42M 61M 82M
shortTermInvestments 175M 182M 259M 268M 262M 273M 316M 331M 367M 375M 423M
cashAndShortTermInvestments 215M 223M 297M 305M 384M 315M 350M 378M 409M 436M 505M
netReceivables 682 000 1M 4M 1M 2M 3M 2M 3M 14M 38M 10M
inventory 0 0 0 -12M 0 0 1 0 0 0 0
otherCurrentAssets 5M 6M 9M 13M 9M 14M 13M 11M 15M 27M 20M
totalCurrentAssets 221M 230M 310M 319M 394M 332M 364M 392M 438M 502M 535M
propertyPlantEquipmentNet 102M 105M 141M 147M 153M 159M 164M 170M 173M 66M 176M
goodwill 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 10M 26M 34M 47M 23M 16M 15M 7M 4M 5M 14M
taxAssets 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 10M 10M 10M 15M 9000 8999 9000 15M 15M 132M 24M
totalNonCurrentAssets 122M 141M 185M 209M 176M 175M 180M 193M 192M 203M 214M
otherAssets 0 0 0 0 0 1 0 0 0 0 0
totalAssets 344M 372M 495M 529M 570M 506M 544M 585M 630M 706M 749M
accountPayables 4M 4M 6M 5M 7M 5M 6M 8M 10M 8M 10M
shortTermDebt 5M 6M 7M 13M 6M 6M 6M 6M 6M 6M 6M
taxPayables 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 5000 0 600 000 0 159 000 685 000 1M 2M 2M 42M 35M
otherCurrentLiabilities 20M 19M 24M 16M 32M 28M 29M 29M 32M 58M 53M
totalCurrentLiabilities 28M 29M 37M 35M 45M 39M 41M 45M 49M 114M 104M
longTermDebt 74M 76M 92M 94M 96M 97M 99M 101M 102M 104M 105M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 12M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 7M 6M 3M 3M 3M 1M 701 000 2M 2M 4M 77M
totalNonCurrentLiabilities 81M 82M 95M 97M 98M 99M 100M 102M 104M 108M 127M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 79M 81M 99M 101M 96M 97M 105M 106M 108M 109M 111M
totalLiabilities 110M 110M 133M 132M 144M 138M 141M 147M 153M 222M 231M
preferredStock 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000
commonStock 115 000 115 000 114 000 114 000 114 000 99 000 99 000 99 000 98 000 97 000 97 000
retainedEarnings -1 502M -1 470M -1 346M -1 298M -1 260M -1 212M -1 168M -1 122M -1 070M -1 051M -994M
accumulatedOtherComprehensiveIncomeLoss 153 000 62 000 835 000 -422 000 -194 000 15 000 -499 000 -587 000 -646 000 -2M -3M
othertotalStockholdersEquity 1 736M 1 731M 1 707M 1 695M 1 686M 1 580M 1 571M 1 561M 1 548M 1 536M 1 516M
totalStockholdersEquity 234M 261M 362M 397M 426M 368M 403M 438M 477M 484M 518M
totalEquity 234M 261M 362M 397M 426M 368M 403M 438M 477M 484M 518M
totalLiabilitiesAndStockholdersEquity 344M 372M 495M 529M 570M 506M 544M 585M 630M 706M 749M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 344M 372M 495M 529M 570M 506M 544M 585M 630M 706M 749M
totalInvestments 185M 208M 293M 315M 285M 289M 316M 338M 371M 380M 437M
totalDebt 79M 81M 99M 101M 102M 104M 105M 106M 108M 109M 111M
netDebt 39M 40M 61M 64M -19M 62M 72M 60M 66M 48M 29M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE FATE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-13 2025-08-12 2024-11-12 2024-08-13 2024-05-09 2024-02-26 2023-11-08 2023-08-08 2023-05-03 2023-02-28 2022-11-03
acceptedDate 2025-11-13 08:35:02 2025-08-12 16:09:49 2024-11-12 16:03:31 2024-08-13 16:08:07 2024-05-09 16:05:10 2024-02-26 16:10:56 2023-11-08 16:05:27 2023-08-08 16:09:52 2023-05-03 16:10:07 2023-02-28 16:06:30 2022-11-03 16:05:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -32M -34M -48M -38M -48M -44M -45M -53M -19M -56M -84M
depreciationAndAmortization 3M 3M -3M 5M 5M 5M 5M 4M 4M 5M 3M
deferredIncomeTax 0 0 0 0 0 6M -3M -3M 0 0 0
stockBasedCompensation 5M 7M 12M 10M 11M 9M 10M 13M 11M 19M 19M
changeInWorkingCapital 504 000 73 000 3M -4M 614 000 -189 000 -3M 14M 12M -33M 10M
accountsReceivables 713 000 1M -2M -190 000 968 000 -288 000 1M 11M 25M -28M 3M
inventory 0 0 0 0 0 -7M 2M 0 0 0 0
accountsPayables 0 0 2M 320 000 -5M -2M -2M 0 -20M 14M 0
otherWorkingCapital -209 000 -937 000 4M -4M 4M 9M -4M 3M 8M -18M 7M
otherNonCashItems -716 000 -1M 6M -4M 22M -13M -2M -4M -37M -11M -4M
netCashProvidedByOperatingActivities -24M -25M -29M -32M -33M -37M -38M -28M -29M -75M -55M
investmentsInPropertyPlantAndEquipment -2M -1M -495 000 -51 000 -86 000 -181 000 -565 000 -2M -3M -7M -9M
acquisitionsNet 0 0 0 0 0 73M -25M 0 0 0 0
purchasesOfInvestments -58M -51M -65M -129M -86M -50M -102M -92M -114M -107M -102M
salesMaturitiesOfInvestments 81M 72M 91M 75M 104M 96M 128M 128M 127M 167M 191M
otherInvestingActivites 3000 122 000 0 0 17M -73M 25M 0 0 0 0
netCashUsedForInvestingActivites 21M 20M 25M -53M 17M 45M 25M 33M 9M 53M 80M
debtRepayment 0 0 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 -95M -662 000 95M -180 000 0 0 207 000 3M 0
commonStockRepurchased 0 0 666 000 0 0 -180 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2M 1M -961 000 2M 95M 0 0 0 0 -1M 1M
netCashUsedProvidedByFinancingActivities 2M 1M 0 1M 95M -180 000 0 58 000 207 000 2M 1M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash -627 000 -4M -4M -84M 79M 9M -13M 5M -19M -21M 27M
cashAtEndOfPeriod 51M 51M 48M 37M 121M 42M 49M 62M 57M 77M 97M
cashAtBeginningOfPeriod 51M 55M 37M 121M 42M 33M 62M 57M 77M 97M 71M
operatingCashFlow -24M -25M -29M -32M -33M -37M -38M -28M -29M -75M -55M
capitalExpenditure -2M -1M -495 000 -51 000 -86 000 -181 000 -565 000 -2M -3M -7M -9M
freeCashFlow -27M -26M -30M -32M -33M -37M -39M -31M -32M -82M -64M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-11 ET (fiscal 2024 q1)
2023 q4
2024-02-26 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-13 08:35 ET
Fate Therapeutics reported for 2025 q3
SEC form 8
2025-11-13 08:32 ET
Fate Therapeutics reported for 2025 q3
SEC form 8
2025-11-13 08:32 ET
Fate Therapeutics published news for 2025 q3
SEC form 8
2025-10-27 11:00 ET
Fate Therapeutics published news for 2025 q3
SEC form 8
2025-10-27 11:00 ET
Fate Therapeutics published news for 2025 q3
SEC form 10
2025-08-12 20:09 ET
Fate Therapeutics reported for 2025 q2
SEC form 8
2025-08-12 20:07 ET
Fate Therapeutics published news for 2025 q2
SEC form 8
2025-08-12 20:07 ET
Fate Therapeutics reported for 2025 q2
SEC form 10
2025-05-13 16:03 ET
Fate Therapeutics reported for 2025 q1
SEC form 8
2025-05-13 16:02 ET
Fate Therapeutics reported for 2025 q1
SEC form 8
2025-05-13 16:02 ET
Fate Therapeutics published news for 2025 q1
SEC form 10
2025-05-13 00:00 ET
Fate Therapeutics reported for 2025 q1
SEC form 10
2025-03-05 16:03 ET
Fate Therapeutics reported for 2024 q4
SEC form 8
2025-03-05 16:02 ET
Fate Therapeutics published news for 2024 q4
SEC form 8
2025-03-05 16:02 ET
Fate Therapeutics reported for 2024 q4
SEC form 10
2025-03-05 00:00 ET
Fate Therapeutics reported for 2024 q4
SEC form 10
2024-11-12 16:03 ET
Fate Therapeutics reported for 2024 q3
SEC form 8
2024-11-12 16:01 ET
Fate Therapeutics published news for 2024 q3
SEC form 8
2024-11-12 16:01 ET
Fate Therapeutics reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Fate Therapeutics reported for 2024 q3
SEC form 10
2024-08-13 16:08 ET
Fate Therapeutics reported for 2024 q2
SEC form 8
2024-08-13 16:06 ET
Fate Therapeutics published news for 2024 q2
SEC form 8
2024-08-13 16:06 ET
Fate Therapeutics reported for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Fate Therapeutics reported for 2024 q2
SEC form 8
2024-05-09 00:00 ET
Fate Therapeutics published news for 2024 q1
SEC form 10
2024-05-09 00:00 ET
Fate Therapeutics reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Fate Therapeutics reported for 2024 q1
SEC form 10
2024-02-26 16:10 ET
Fate Therapeutics reported for 2023 q4
SEC form 8
2024-02-26 16:03 ET
Fate Therapeutics published news for 2023 q4
SEC form 8
2024-02-26 16:03 ET
Fate Therapeutics reported for 2023 q4
SEC form 10
2024-02-26 00:00 ET
Fate Therapeutics reported for 2023 q4
SEC form 10
2023-11-08 16:05 ET
Fate Therapeutics reported for 2023 q3
SEC form 8
2023-11-08 16:03 ET
Fate Therapeutics reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Fate Therapeutics reported for 2023 q3
SEC form 10
2023-08-08 16:09 ET
Fate Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:07 ET
Fate Therapeutics reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Fate Therapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Fate Therapeutics reported for 2023 q2
SEC form 6
2023-06-09 16:08 ET
Fate Therapeutics published news for 2023 q1
SEC form 6
2023-06-08 16:12 ET
Fate Therapeutics published news for 2023 q1
SEC form 6
2023-06-07 08:52 ET
Fate Therapeutics published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Fate Therapeutics reported for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Fate Therapeutics reported for 2023 q1
SEC form 6
2023-04-19 16:06 ET
Fate Therapeutics published news for 2023 q1
SEC form 10
2023-02-28 16:06 ET
Fate Therapeutics reported for 2022 q4
SEC form 6
2023-02-28 16:03 ET
Fate Therapeutics reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Fate Therapeutics reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Fate Therapeutics reported for 2022 q4
SEC form 6
2023-01-05 17:04 ET
Fate Therapeutics published news for 2022 q4
SEC form 6
2022-11-07 13:21 ET
Fate Therapeutics published news for 2022 q3
SEC form 10
2022-11-03 16:05 ET
Fate Therapeutics reported for 2022 q3
SEC form 6
2022-11-03 16:03 ET
Fate Therapeutics reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Fate Therapeutics reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Fate Therapeutics reported for 2022 q3
SEC form 10
2022-08-03 16:08 ET
Fate Therapeutics reported for 2022 q2
SEC form 6
2022-08-03 16:03 ET
Fate Therapeutics published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Fate Therapeutics reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Fate Therapeutics reported for 2022 q2
SEC form 6
2022-06-30 16:06 ET
Fate Therapeutics published news for 2022 q1
SEC form 6
2022-06-29 17:01 ET
Fate Therapeutics published news for 2022 q1
SEC form 6
2022-06-13 16:10 ET
Fate Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 16:16 ET
Fate Therapeutics reported for 2022 q1
SEC form 6
2022-05-04 16:06 ET
Fate Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Fate Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Fate Therapeutics reported for 2022 q1
SEC form 6
2022-04-25 16:03 ET
Fate Therapeutics published news for 2022 q1
SEC form 10
2022-02-28 16:13 ET
Fate Therapeutics published news for 2021 q4
SEC form 6
2022-02-28 16:06 ET
Fate Therapeutics published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Fate Therapeutics published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Fate Therapeutics published news for 2021 q4
SEC form 6
2021-12-14 17:28 ET
Fate Therapeutics published news for 2021 q3
SEC form 6
2021-11-04 16:59 ET
Fate Therapeutics published news for 2021 q3
SEC form 10
2021-11-04 16:13 ET
Fate Therapeutics published news for 2021 q3
SEC form 6
2021-11-04 16:07 ET
Fate Therapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Fate Therapeutics published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Fate Therapeutics published news for 2021 q3
SEC form 10
2021-08-04 16:13 ET
Fate Therapeutics published news for 2021 q2
SEC form 6
2021-08-04 16:05 ET
Fate Therapeutics published news for 2021 q2
SEC form 6
2021-08-04 09:20 ET
Fate Therapeutics published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Fate Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Fate Therapeutics reported for 2021 q2
SEC form 6
2021-06-07 16:50 ET
Fate Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 16:07 ET
Fate Therapeutics published news for 2021 q1
SEC form 6
2021-05-05 16:01 ET
Fate Therapeutics published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Fate Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Fate Therapeutics published news for 2021 q1
SEC form 6
2021-04-21 16:11 ET
Fate Therapeutics published news for 2021 q1
SEC form 6
2021-04-07 16:49 ET
Fate Therapeutics published news for 2021 q1
SEC form 6
2021-04-02 16:32 ET
Fate Therapeutics published news for 2021 q1
SEC form 6
2021-03-25 16:01 ET
Fate Therapeutics published news for 2020 q4
SEC form 10
2021-02-24 16:09 ET
Fate Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 16:01 ET
Fate Therapeutics published news for 2020 q4
SEC form 6
2021-01-08 16:02 ET
Fate Therapeutics published news for 2020 q4
SEC form 6
2020-12-22 16:01 ET
Fate Therapeutics published news for 2020 q3
SEC form 6
2020-12-07 09:00 ET
Fate Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 16:07 ET
Fate Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 16:02 ET
Fate Therapeutics published news for 2020 q3